Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
5-methoxytryptamine-alpha-lipoate
- Development stage
- Preclinical
- Lead developer
- Cancer Hospital of Guangxi Medical University
- Modality
- Small Molecules, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
5-methoxytryptamine-alpha-lipoate (MLA) is an investigational radioprotective agent and antioxidant synthesized from melatonin (5-methoxytryptamine) and alpha-lipoic acid. Originally developed by the Institute of Radiation Medicine of the Chinese Academy of Medical Sciences, MLA acts as a reactive oxygen species (ROS) scavenger to protect against radiation-induced hematopoietic injury and myelosuppression. In clinical development, MLA is formulated into CD5-targeted lipid nanoparticles (MLA@CD5LNPs) by Guangxi Medical University Cancer Hospital. This targeted formulation is designed to specifically home to exhausted T cells, reducing post-radiotherapy oxidative stress in CD8+ T cells, maintaining mitochondrial homeostasis, and restoring anti-tumor cytotoxicity and systemic immune responses in patients with nasopharyngeal carcinoma.
- Other names
- 5-methoxytryptamine-alpha-lipoic acid5-methoxytryptamine-alpha-lipoic acid salt5-methoxytryptamine-alpha-lipoate5-methoxytryptamine-α-lipoic acid5-methoxytryptamine-α-lipoic acid salt5-methoxytryptamine-α-lipoate5-甲氧基色胺-α-硫辛酸盐
02
Targets
CD5 (T-cell surface glycoprotein CD5)NOX4 (NADPH oxidase 4)5-HT (Serotonin receptors)
Beyond the preview
Go deeper on 5-methoxytryptamine-alpha-lipoate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 5-methoxytryptamine-alpha-lipoate.